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Abstract  
Glioblastoma (GBM) is a universally fatal brain cancer, for which novel therapies targeting specific 
underlying oncogenic events are urgently needed. While the Wnt pathway has been shown to be 
frequently activated in GBM, constituting a potential therapeutic target, the relevance of WNT6, 
an activator of this pathway, remains unknown.  
Methods: WNT6 protein and mRNA levels were evaluated in GBM. WNT6 levels were silenced or 
overexpressed in GBM cells to assess functional effects in vitro and in vivo. Phospho-kinase arrays 
and TCF/LEF reporter assays were used to identify WNT6-signaling pathways, and significant 
associations with stem-cell features and cancer-related pathways were validated in patients. 
Survival analyses were performed with Cox regression and Log-rank tests. Meta-analyses were 
used to calculate the estimated pooled effect. 
Results: We show that WNT6 is significantly overexpressed in GBMs, as compared to lower-grade 
gliomas and normal brain, at mRNA and protein levels. Functionally, WNT6 increases typical 
oncogenic activities in GBM cells, including viability, proliferation, glioma stem-cell capacity, 
invasion, migration, and resistance to temozolomide chemotherapy. Concordantly, in in vivo 
orthotopic GBM mice models, using both overexpressing and silencing models, WNT6 expression 
was associated with shorter overall survival, and increased features of tumor aggressiveness. 
Mechanistically, WNT6 contributes to activate typical oncogenic pathways, including Src and 
STAT, which intertwined with the WNT pathway may be critical effectors of WNT6-associated 
aggressiveness in GBM. Clinically, we establish WNT6 as an independent prognostic biomarker of 
shorter survival in GBM patients from several independent cohorts.  
Conclusion: Our findings establish WNT6 as a novel oncogene in GBM, opening opportunities to 
develop more rational therapies to treat this highly-aggressive tumor. 
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Introduction 
Glioblastoma (GBM) is the most lethal tumor of the central nervous system in adults. 
Despite recent advances in the understanding of the oncogenic molecular mechanisms, and 
improvements in neuroimaging technologies, surgery and adjuvant treatments, patients with 
GBM still exhibit a rapid unfavorable clinical evolution. The median survival of patients is 15 
months after diagnosis, a scenario that has not changed significantly in the last decades [1-4]. In 
combination with their resistance to most conventional therapies, including radiotherapy and 
temozolomide (TMZ), GBMs are highly infiltrative and diffuse, impeding complete surgical 
resections. In this context, understanding the key underlying molecular mechanisms contributing 
to the aggressiveness of this tumor may be a critical step in the design of new and more effective 
precision therapies. 
The WNT signaling pathway displays pleiotropic physiological functions, ranging from 
neurogenesis to stem cell proliferation, and has been implicated in various human cancers, 
including glioma [5-8]. This pathway is particularly relevant in the context of cancer stem cells 
(CSC), which have been pointed as critical mediators of cancer recurrence and resistance to radio- 
and chemo-therapy [7, 9-11]. Therefore, novel therapeutic strategies targeting particular 
components of the WNT pathway have been widely explored [9, 10, 12]. The WNT6 ligand is an 
activator of the WNT pathway, which only recently was associated with chemoresistance in 
gastric and bladder cancers [13, 14], poor prognosis of esophageal squamous cell carcinoma 
patients [15], and increased risk to develop colorectal adenoma [16]. Importantly, no studies to 
date have explored the relevance of WNT6 in human glioma. 
In this work, we show WNT6 is overexpressed in GBM, the most common and malignant 
glioma, and displays typical hallmark oncogenic functions in both in vitro and in vivo GBM models 
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by affecting the activity of classic oncogenic signaling pathways, including WNT, SFK and STAT 
pathways. Critically, we provide data from several independent GBM patient cohorts establishing 
WNT6 as a prognostic biomarker associated with shorter overall survival.  
 
Results 
WNT6 is overexpressed in primary GBM tissues 
While high WNT6 expression levels were previously observed in different human cancer 
cell lines [13, 17, 18], little is known about its specific roles in tumors, particularly in GBM. In order 
to address this, we first analyzed gene expression array data from normal brains, lower-grade 
gliomas (LGG, WHO grades II and III) and GBM (WHO grade IV) patients deposited in TCGA [19]. 
When compared to normal samples, WNT6 was not overexpressed in any of the LGG patients 
(0/27), while 15.6% of GBM patients (89/572) presented high WNT6 levels (Figure 1A; p = 0.026). 
Concordantly, testing the protein levels of WNT6 by immunohistochemistry (IHC) in another 
dataset of glioma tissues (from Hospital Santo António; HSA) showed that only GBMs present high 
expression of WNT6 protein (16.3%; Figure 1B bottom; p = 0.037). WNT6 immunoreactivity 
expression in glioma showed to be mainly cytoplasmic (closed arrowheads), with a diffuse pattern 
where almost all tumor cells are positive (Figure 1B, b and c), or a more scattered pattern (Figure 
1B, d). Tumor-infiltrating lymphocytes were negative for WNT6 expression (arrow; Figure 1B, e), 
with endothelial cells being negative or showing some faint immunoreactivity (open arrowheads; 
Figure 1B, b, c, d, and f). Representative images of positive and negative controls, and hematoxylin 
and eosin stainings are displayed in Supplementary Figure S1. Together, these results show WNT6 
mRNA and protein levels associate with high glioma grade, suggesting it may be important in the 
pathophysiology of glioma. 
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High WNT6 expression is indiscriminately present in all molecular subtypes of GBM 
Several efforts have been made to stratify GBM into molecular subgroups [20-27]. We 
evaluated the levels of WNT6 expression among the GBM subtypes described by Verhaak et al 
(classical, mesenchymal, neural and proneural) [28] in a total of 4 independent cohorts, totalizing 
201 patients from TCGA, 59 from Freije, 159 from Gravendeel and 26 from Vital datasets. High 
levels of WNT6 were detected with no significant differences in subsets of patients of each GBM 
molecular subtype in all datasets (Figure 1A and Supplementary Figure S2), suggesting WNT6 
activation in GBM is independent of these molecular signatures. 
 
WNT6 has oncogenic functions and promotes GBM aggressiveness in vitro 
To address whether WNT6 expression influences typical cancer hallmark features of GBM 
cells, WNT6 expression was silenced in U373MG and SNB19 cell lines by shRNA, resulting in 
significantly decreased mRNA and protein levels (Figure 2A and B), as well as overexpressed in 
U87MG cells, which do not express WNT6 endogenously (Supplementary Figure S3A). WNT6-low 
cells presented a significantly lower viability when compared with the corresponding WNT6-high 
counterparts (Figure 2C and D, and Supplementary S3B and C). Concomitantly, WNT6 silencing 
significantly decreased proliferation of GBM cells (Figure 2E). Considering GBM cells display 
remarkable migration and invasion potentials, we tested how WNT6 affects these hallmark 
features of GBM. Wound healing migration assays and matrigel invasion assays showed that 
WNT6 significantly increases the capacity of GBM cells to migrate and invade (Figure 2F-K and 
Supplementary Figure S3D and E). Together, these data suggest WNT6 is an important factor 
regulating several cancer hallmarks, which might influence GBM aggressiveness. 
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WNT6 increases resistance to temozolomide chemotherapy in GBM cells 
Previous reports have described the relevance of the WNT pathway in increased 
resistance of many cancers to radio- and chemo-therapy [7-9, 15]. In this context, we tested 
whether WNT6 expression may have an impact in the sensitivity of GBM cells to clinically-relevant 
therapies, including TMZ chemotherapy and radiation. Interestingly, WNT6-silenced GBM cells 
were significantly more sensitive to TMZ-mediated cell death than their respective control cells 
(Figure 3A and B). In contrast, WNT6 did not affect sensitivity of GBM cells to radiation treatments 
(Supplementary Figure S4). Overall, these results suggest WNT6 promotes resistance of GBM cells 
to TMZ, with potential clinical implications as TMZ is still the standard-of-care for these patients. 
 
WNT6 promotes glioblastoma stem cell features 
Due to the critical roles of GBM stem cells (GSC) in the pathophysiology and clinical 
outcome of GBM patients, we investigated how WNT6 may affect GBM cells’ stemness. 
Interestingly, WNT6-silenced U373 and SNB19 cells showed prominent decreased levels of 
NESTIN and SOX2 proteins, two common markers of GSCs (Figure 4A). In addition, WNT6 
expression resulted in significantly higher capacities of U373, SNB19 and U87 cells to form 
neurospheres when cultured under GSC conditions (Figure 4B and C and Supplementary Figure 
S3F and G), functionally suggesting WNT6 contributes to the stem cell phenotype of GBM cells. 
Concordantly, WNT6 expression resulted in significantly increased neurosphere-forming 
frequency in a limiting dilution sphere-forming assay (1/3.81 for shCtrl vs 1/16.11 for shWNT6; p 
= 0.01, likelihood ratio test, Figure 4D for U373 cells; SNB19 cells with WNT6-silencing did not 
form spheres in the tested conditions – data not shown; 1/62.3 for U87-Ctrl vs 1/24.6 for U87-
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WNT6; p = 0.004, likelihood ratio test, Supplementary Figure S3H), an assay that allows the 
quantification of cells with stem-like properties that are capable of forming a new neurosphere 
derived from a single cell. 
In addition to sphere-based stem cell assays, we then tested U373 and SNB19 cells 
cultured under specific adherent conditions that allow GSC expansion (neurosphere medium 
supplemented with B27, EGF and FGF in laminin-coated wells) [29]. GBM cells acquired a more 
elongated phenotype in these adherent stem cell conditions (Figure 4E), as previously described 
[29, 30]. Concordantly with our findings in “non-stem cell” conditions (Figure 2C and D), WNT6 
silencing significantly impaired cell viability of U373 and SNB19 GBM cells grown in adherent stem 
cell-like conditions (Figure 4F). Globally, these data suggest WNT6 has an important functional 
role in the formation and maintenance of GSCs. 
 
WNT6 is associated with stem cell-related genes in GBM clinical samples 
To further translate our results to the clinical setting, we evaluated correlations between 
the expression levels of WNT6 and typical stem cell-related genes in GBM patients from TCGA. 
Interestingly, heatmap analyses revealed common patterns of gene expression between various 
stem cell-related genes and WNT6 (Figure 4G), and individual correlation graphs showed 
statistically significant positive correlations between the expression levels of WNT6 and these 
genes (p < 0.0001; Figure 4H and Supplementary Figure S5). These data from GBM patients fit 
well with our in vitro findings, further suggesting WNT6 contributes to the stem cell phenotype 
of GBM cells. 
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High WNT6 levels accelerate GBM-associated death in intracranial mice models 
To expand our findings to in vivo models, U373-shCtrl and U373-shWNT6 (Figure 5), or 
U87-Ctrl and U87-WNT6 cells (Supplementary Figure S3I-L) were orthotopically-injected in the 
brain of NSG mice. Importantly, all mice bearing WNT6-low tumors presented significantly 
delayed evidences of GBM-related neurological symptoms and slower body weight loss than mice 
bearing WNT6-high tumors (Figure 5A and Supplementary Figure S3I). This was accompanied by 
a significantly longer overall survival of U373-shWNT6 and U87-Ctrl mice as compared to mice 
injected with U373-shCtrl and U87-WNT6 cells, respectively (Figure 5B and Supplementary Figure 
S3J), implicating high levels of WNT6 as a negative prognostic biomarker in orthotopic GBM in 
vivo models. Post-mortem hematoxylin & eosin (H&E) analyses confirmed GBM formation in all 
animals (Figure 5C and Supplementary Figure S3K), with a very invasive phenotype typical of GBM. 
IHC confirmed long-term WNT6 silencing and overexpression in U373-shWNT6 and U87-WNT6 
tumors, respectively (Figure 5D and Supplementary Figure S3L). Histologically, shWNT6 GBM 
tumors also presented: i) lower proliferative activity, as observed by decreased Ki-67 and Cyclin 
D1 immuno-stainings (Figure 5E); ii) diminished expression of the stem cell marker SOX2, despite 
no alteration in the expression of NESTIN (Figure 5F); and iii) decreased expression of BCL2 
protein, a critical anti-apoptotic molecule (Figure 5G). Together, these data support WNT6 as a 
critical mediator of GBM aggressiveness in vivo, identifying some molecular mediators that might 
sustain this aggressive phenotype, in line with what was observed in the in vitro assays. 
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WNT6 acts through β-catenin-dependent WNT signaling and downstream targets of SFKs/STAT 
pathways 
To explore the underlying molecular mechanisms by which WNT6 influences GBM 
aggressiveness, the activation status of a large variety of cancer-related kinases was evaluated in 
U373 and SNB19 cell lines using a human phospho-kinase antibody array (Figure 6A and B). The 
phosphorylation levels of 4 proteins belonging to the non-receptor tyrosine Src family kinases 
[SFK; namely p-Fgr (Y412), p-Yes (Y426), p-Fyn (Y420) and p-Src (Y419)], and p-HSP27 (S78/S82), 
a member of the heat shock protein (HSP) family, were significantly decreased upon WNT6 
silencing in U373 and SNB19 GBM cells (Figure 6A and B). In addition, the total levels of β-catenin 
were also decreased upon WNT6 silencing in both cell lines (Figure 6A and B).  
Of note, other signaling pathways were concordantly affected upon WNT6 silencing in 
both cell lines, but at the level of different proteins. For example, the PI3K/AKT/mTOR pathway 
activation was decreased in U373 cells by directly affecting the phosphorylation of activating 
residues of AKT and mTOR, two of the major mediators of this pathway. While these specific 
proteins were not significantly altered in SNB19 cells, other downstream targets of this pathway, 
such as p70 S6K and eNOS, showed decreased phosphorylation levels, globally resulting in similar 
decreased signaling of the PI3K pathway. It is also interesting to note that STAT3 phosphorylation 
levels were altered in WNT6-silenced U373 and SNB19 cells, but at different residues: serine 727 
(S727) phosphorylation was increased in U373 cells, while tyrosine 705 (Y705) phosphorylation 
was decreased in SNB19 cells (Figure 6A and B). Despite the contrasting phosphorylation levels of 
these STAT3 residues, the biological meaning is the same, as S727 phosphorylation inactivates, 
while Y705 phosphorylation activates STAT3 activity [31]. 
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In addition to these signaling pathways concordantly affected in both cell lines, cell-line 
specific effects were also observed, such as alterations in the phosphorylation of JNK, GSK-3a/b, 
and EGFR in U373 cells, and of STAT2, STAT5a, STAT5a/b, PDGFRb, and c-Jun in SNB19 cells. Again, 
despite these examples of cell-specific effects, the silencing of WNT6 consistently resulted in a 
decreased activation status of these cancer-related pathways in GBM. 
To further validate the results obtained in the phospho-kinase arrays, the phosphorylation 
status of 3 proteins was assessed by western blot (WB) and normalized to α-tubulin (reference 
protein; Figure 6C and D), as performed in the arrays. Interestingly, WBs show a slight decrease 
of p-STAT3 Y705 in U373 cells, and a more prominent decrease in SNB19 cells, as evidenced in the 
phospho-arrays. Similarly, a significant decrease of non-p-β-cat S33/S37/T41 levels upon WNT6 
silencing was observed in both cell lines, while only U373 presented decreased p-AKT S473 
phosphorylation levels, further validating the phospho-arrays data.  
To confirm that WNT6 activates the canonical WNT/β-catenin signaling pathway, TCF/LEF 
reporter assays were performed in both U373 shCtrl/shWNT6 cells and in U87 Ctrl/WNT6 cells. 
Concordantly to the aforementioned results, GBM cells with high levels of WNT6 presented a 
significantly increased activation of the Wnt canonical pathway as compared to their negative 
counterparts (Supplementary Figure S6A-D). 
Together, these results suggest that WNT6 acts not only through β-catenin-dependent 
WNT signaling, but also through the activation of downstream targets of SFKs/STAT pathways, 
highlighting WNT6 as a critical molecule involved in a variety of crucial signaling pathways in GBM, 
which associate with the observed oncogenic functional effects in vitro and in vivo, and reveal 
putative novel targets for therapeutic interventions in WNT6-high GBMs. 
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WNT6-correlated genes are enriched for WNT, AKT, SRC, MYC, JNK and MAPK signaling 
pathways in GBM patients 
To expand the WNT6-associated molecular mechanisms detected in vitro (Figure 6A-D) to 
clinical samples of GBM, gene set enrichment analysis (GSEA) were performed to identify 
transcriptomic signatures reminiscent of WNT6-associated genes in patients (Figure 6E). The gene 
expression profiles of GBM patients from TCGA (n = 573) were gathered, and WNT6 expression 
used as a continuous label (i.e., all genes were ranked based on their correlation with WNT6). 
WNT6-positively correlated genes revealed to be significantly enriched for genes up-regulated 
upon activation of WNT, AKT, SRC, MYC, JNK and MAPK signaling (all enrichment scores, ES > 0.3, 
and false discovery rates, FDR < 0.3; Figure 6E). Concordantly, WNT6-negatively correlated genes 
were enriched for genes down-regulated upon WNT signaling activation (ES > 0.3 and FDR < 0.3; 
Figure 6E top left). Overall, these transcriptomic results derived from GBM samples fit well with 
our in vitro phosphorylation data, where the same pathways were shown to be altered upon 
WNT6 silencing, further supporting the critical links between WNT6 and key oncogenic signaling 
pathways associated with glioma aggressiveness.  
 
High levels of WNT6 expression associate with shorter overall survival in GBM patients 
Since our data demonstrated critical roles of WNT6 in GBM aggressiveness in vitro and in 
vivo, and its association with GBM’s key signaling pathways, we investigated the clinical 
significance of WNT6 expression in a variety of GBM patient datasets. In our Portuguese dataset 
(Hospital Braga and Hospital Santa Maria, n = 51), high levels of WNT6 mRNA were significantly 
associated with shorter overall survival (OS) of GBM patients (p = 0.032; log-rank test; Figure 7A). 
Importantly, this association between high WNT6 mRNA levels and poor prognosis in GBM 
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patients was further validated in 3 additional independent datasets: Freije (n = 59) [24], 
Gravendeel (n = 159) [32] and Vital (n = 26) [33] datasets (p = 0.006, p = 0.029, p = 0.02, 
respectively; Figure 7B-D). These findings were then validated in 407 GBM patients with available 
survival data from TCGA (Table 1), in which a multivariable Cox model showed a statistically 
significant association between higher values of WNT6 expression and shorter OS of GBM patients 
(p = 0.030), independently of other prognostic variables, including patient age (p < 0.0001), 
Karnofsky performance status (KPS; p = 0.001), gender (p = 0.037) and the treatment with chemo- 
or radio-therapy (p < 0.0001; Table 1). Moreover, high levels of WNT6 protein expression, 
evaluated by IHC in a GBM Brazilian cohort (n = 87), also showed an evident trend for shorter OS 
(p = 0.069; Supplementary Figure S7), highlighting that both mRNA and protein levels of WNT6 
may be used as a clinically-valuable biomarker. To reinforce this association, a meta-analysis 
including all independent datasets showed that WNT6-high expression is globally associated with 
shorter survival of GBM patients (Hazard Ratio = 1.637; 95% confidence interval: 1.285 – 2.086; p 
< 0.0001; Figure 7E). Together, these results suggest that WNT6 expression may be a new 
prognostic factor useful for the stratification of GBM patients. 
 
Discussion 
Deregulated signaling of the WNT pathway has been reported in several human cancers, 
including GBM, and has been associated with treatment resistance [13, 34-36]. This is partly due 
to stem-cell features sustained by WNT signaling, such as increased proliferation and migration 
[34]. The present study is the first dissecting the functional roles and underlying molecular 
mechanisms mediated by WNT6 activation in human GBM, establishing it as a clinically-relevant 
prognostic biomarker (Figures 7 and 8, Table 1, and Supplementary Figure S7). Due to its critical 
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functions during embryogenesis [37-42], deregulated expression of WNT6 in adults may favor 
tumorigenesis [13-16]. Our data show that the expression of WNT6 in gliomas is grade-
dependent, at the gene and protein levels (Figure 1), similarly to what was previously described 
for other WNT ligands [5, 6, 43-46], thus associating WNT6 with increased malignancy of gliomas. 
In addition, our findings demonstrate prominent effects of WNT6 on GBM cell viability, 
proliferation, glioma stem cell capacity, invasion, migration and sensitivity to TMZ-based 
chemotherapy, comprehensively implicating WNT6 as an important oncogenic factor in glioma 
(Figures 2, 3 and 4, and Supplementary Figure S3). This is in agreement with the known effects of 
other WNT ligands in GBM [5, 6, 44, 46, 47]. According to the definition of CSC [48], we showed 
that WNT6 expression not only correlates with the expression of cancer-stem cell associated 
genes, but also functionally impacts on the self-renewal capacity of GSC (Figure 4 and 
Supplementary Figure S3F-H). Concordantly with the functional effects, molecular data also 
showed WNT6 associates with typical GSC markers, both in GBM cells and patient samples.  
Considering the global effects of WNT6 in GSC phenotypes (Figure 4 and Supplementary 
Figure S3F-H), cell motility capacity (Figure 2 and Supplementary Figure S3D and E), and resistance 
to chemotherapy (Figure 3), it will be interesting to evaluate its potential value as a biomarker for 
tumor recurrence, which is of paramount importance to the clinical management of GBM as these 
patients recur almost universally after treatment. Importantly, we also demonstrated that WNT6 
is a novel biomarker of GBM prognosis, as patients with WNT6-high tumors from a variety of 
independent datasets presented a significantly shorter OS than WNT6-low tumors (Figure 7, Table 
1 and Supplementary Figure S7), a clinical finding that is in agreement with our in vivo data (Figure 
5 and Supplementary Figure S3I and J). This might be linked to the WNT6 oncogenic activities, 
such as increased invasion/migration, hampering complete tumor resection, increased tumor 
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relapse probability due to its roles in GSC maintenance (Figure 4 and Supplementary Figure S3F-
H), and the response to TMZ treatment (Figure 3), which is still the gold-standard 
chemotherapeutic drug used for GBM patients. These findings fit well with previous reports 
describing that WNT6 increases the chemo-resistance of gastric [13] and bladder [14] cancer, and 
associates with the overall and disease-free survivals of esophageal squamous cell carcinoma 
patients [15]. Together, these data implicate WNT6 as a novel prognostic biomarker and putative 
therapeutic target for GBM patients. The fact that WNT6 levels can be easily assessed at the 
mRNA or protein levels with routine molecular biology techniques may also facilitate the 
widespread implementation of this biomarker in the clinical settings. 
Taking into consideration that (i) the first step for designing novel therapeutic strategies 
requires not only the identification of new molecular targets, but also the understanding of their 
functional mechanisms, and (ii) nothing was still known on WNT6-mediated signaling mechanisms 
in GBM or any other cancer type, our phospho-kinase arrays provide the first data on the 
activation status of several cancer-related pathways that may be regulated by WNT6 (Figure 6). 
The effects observed in β-catenin in U373 and SNB19 cells clearly suggest that WNT6 might act 
through the canonical WNT pathway in GBM, which was further validated with the TCF/LEF 
reporter assays in U373 and U87 cells (Supplementary Figure S6). In addition, WNT6 silencing led 
to reduced phosphorylation/activation states of 4 non-receptor tyrosine Src kinases (Fgr, Yes, Fyn 
and Src), which have been described to contribute to the activation of downstream targets of 
RTKs, such as EGFR, influencing glioma aggressiveness [49-51]. WNT6 silencing also resulted in 
decreased phosphorylation of HSP27, an anti-apoptotic protein [52], associated with increased 
cell proliferation and decreased Fas-induced apoptosis in prostate cancer [53], and shown to 
mediate the activation of p38/ERK (MAPK) pro-survival signaling in cervical cancer cells [54]. 
- 16 - 
Nevertheless, other cell-line specific alterations in WNT6-silenced cells, namely in p-AKT, p-TOR 
and p-PRAS40 in U373 cells, clearly demonstrate the association between WNT6 and the 
activation of the PI3K/AKT/mTOR pathway, which is known to have a major role in the oncogenic 
process of GBM cells [55]. Regarding p-STAT3 alterations upon WNT6 silencing, it was reported 
that reduced p-STAT3 S727 or increased p-STAT3 Y705 lead to more aggressive glioma tumors in 
vivo, and enhance glioma proliferation and invasion in vitro [31], which also fits well with a WNT6-
mediated oncogenic role in GBM. Importantly, GSEA data derived from clinical GBM samples 
further supported the molecular links between WNT6 and these cancer-related pathways. In this 
context, our results together with the reports associating the WNT pathway with the MAPK, PI3K 
and STAT3 pathways [56-63] strongly support a role of WNT6 in the regulation of these cancer-
related pathways and suggest that WNT6 acts, at least partly, through the canonical WNT 
signaling, independently of the expression of other well-known canonical WNT ligands (WNT1 
and WNT3a; Supplementary Figure S8). Future work should focus on the potential predictive 
value of WNT6 for targeted therapies with specific inhibitors of WNT-related pathways (e.g., 
LGK974, currently tested in clinical trials for several solid tumors; NCT01351103).  
In summary, this work provides significant contributions to the neuro-oncology field, 
profiting from the understanding of WNT6-mediated signaling pathways and from the portrayal 
of the functional roles and clinical value of WNT6 in GBM, potentially impacting on the prognostic 
stratification and aiding in rationale treatment decisions for GBM patients.  
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Materials and Methods 
TCGA data analysis in glioma patients 
All gene expression data from samples hybridized by the University of North Carolina, 
Lineberger Comprehensive Cancer Center, using Agilent G4502A 244K, were downloaded from 
TCGA (https://portal.gdc.cancer.gov/) [19], including 572 GBMs, 27 LGGs, and 10 unmatched non-
tumoral patient samples. To prevent duplicated entries from the same patient – when more than 
one portion per patient was available – the median expression value was used. Three probe sets 
hit WNT6 gene (A_23_P119916, A_32_P159877 and A_24_P208513). The provided value was pre-
processed and normalized according to “level 3” specifications of TCGA. WNT6 overexpression in 
glioma samples was considered when higher than in non-tumoral samples (“level 3” value ≥ 0.41). 
Clinical data of each patient was provided by the biospecimen core resources and includes 
information about patients’ age at diagnosis, gender, KPS and days to death and to last follow-
up. 
 
Freije, Gravendeel and Vital datasets 
WNT6 expression microarray data from Freije (n = 59) [24], Gravendeel n = 159 [32], and 
Vital (n = 26) [33] datasets of GBM patients were obtained in the GlioVis data portal [64]. The top 
17% of tumors expressing highest levels of WNT6 were classified as WNT6-high in Freije (n = 
10/59) and Gravendeel (n = 27/159) datasets, similarly to the cutoff used for TCGA, and the top 
39% for the Vital (n = 10/26) dataset due to the small number of patients. Clinical data included 
GBM subtype classification, OS and vital status of the patients.  
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Glioma primary tissues 
Glioma tumor specimens were obtained from patients who performed a craniotomy for 
tumor removal or stereotaxic biopsy at 4 different hospitals: Hospital Braga (HB), Hospital Santa 
Maria (HSM, Centro Hospitalar Lisboa Norte; samples requested from Biobanco-iMM, Lisbon 
Academic Medical Center, Lisbon, Portugal) and Hospital Santo António (HSA, Centro Hospitalar 
Porto), Portugal, and Hospital de Câncer de Barretos, Brazil. Samples from HB and HSM were 
reserved for RNA-based studies, transported in dry ice to the lab and stored at -80 ᵒC. Samples 
from HSA and Brazil were formalin-fixed and paraffin-embedded and used for IHC analysis. 
Samples from Brazil were organized in triplicates into tissue microarrays (TMAs) [65]. Tumors 
were classified according to WHO 2007 [66] and only patients with glial tumor histological 
diagnosis were included in the study.  
 
Immunohistochemistry 
Tissues sections were deparaffinized and rehydrated by xylene and ethanol series. Sodium 
citrate buffer (10 mM, 0.05% Tween 20, pH 6) was used for antigen retrieval. Endogenous 
peroxidase activity was blocked with 3% H2O2 in TBS 1x for 10 min. Immunohistochemical staining 
was performed using the LabVision kit (UltraVision Large Volume Detection System Anti-
polyvalent, HRP) according to the manufacturer’s instructions. WNT6, Ki-67, Cyclin D1, SOX2, 
Nestin, GFAP and BCL2 antibodies were used (see Supplementary Table S1 for details). Concerning 
Ki-67 staining, before antigen retrieval, tissues were permeabilized using TBS-Tween 0.5%, for 10 
min. DAB substrate (DAKO) was used as chromogen, followed by counterstaining with 
hematoxylin. The TMA from the Brazilian cohort was blind-scored by a pathologist based on 
WNT6 staining intensity: 1 = weak, 2 = moderate and 3 = strong. The average of the triplicate 
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spots was calculated and used for the survival analysis. An average > 2 was considered as WNT6 
high expression. 
 
Cell lines and culture conditions 
Human GBM cell lines U373MG and U87MG (kindly provided by Dr. Joseph Costello, 
University of California, San Francisco), and SNB19 (obtained from German Collection of 
Microorganisms and Cell Cultures) were cultured in DMEM (Biochrom) supplemented with 10% 
Fetal Bovine Serum (FBS; Biochrom). Cells were maintained in a humidified atmosphere at 37 ᵒC 
and 5% (v/v) CO2. These conditions were maintained throughout the studies, unless otherwise 
stated. Testing for mycoplasma contamination was performed every month.  
 
WNT6-silencing by shRNA in GBM cells 
U373MG and SNB19 cell lines were plated at 70 000 cell/well (24-well plate) and 100 000 
cells/well (12-well plate), respectively. Cells were transfected with WNT6 gene-specific shRNA 
expression vector inserted in a pRS plasmid (TR308360, clones TI333434 and TI333435 from 
Origene; named U373-shWNT6 or SNB19-shWNT6, respectively) or with a scrambled negative 
control non-effective shRNA in a pRS plasmid (TR30012, Origene; named U373-shCtrl or SNB19-
shCtrl). Lipofectamine 3000 (Invitrogen) transfection reagent was used according to 
manufacturer’s recommendations (ratio plasmid/lipofectamine, 1:2.5). Stable transfection was 
achieved by selecting transfected clones with puromycin (1 µg/mL).  
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WNT6 overexpression in GBM cells 
U87MG cells were plated at 200 000 cell/well (6-well plate). Cells were transfected with 
the pcDNA-Wnt6 vector (gift from Dr. Marian Waterman; Addgene plasmid #35913) [67] or with 
the respective empty vector (pcDNA3.2 GW delCMV; gift from Dr. Edward Hsiao; Addgene 
plasmid #29496) [68]. Lipofectamine 3000 (Invitrogen) transfection reagent was used according 
to manufacturer’s recommendations (4 µL of Lipofectamine 3000 per 1 µg of DNA). Stable 
transfection was achieved by selecting transfected clones with geneticin (800 µg/mL).  
 
qRT-PCR 
Total RNA was extracted from GBM patients’ tissues and cell lines using the TRIzol method 
(Invitrogen) and cDNA from 1 µg of the total RNA was then synthesized (RT-Phusion Kit, Thermo 
Scientific). The levels of WNT6 and TBP (reference gene) were assessed by quantitative reverse 
transcription-PCR (qRT-PCR; KAPA SYBR® FAST qPCR Kit, KAPABIOSYSTEMS or PowerUp™ SYBR™ 
Green Master Mix, ThermoFisher Scientific, for cell lines and GBM patient’s samples, respectively) 
with the following sets of primers: WNT6 Fwd 5’–GACGAGAAGTCGAGGCTCTTT–3’ and Rev 5’–
CGAAATGGAGGCAGCTTCT–3’; TBP Fwd 5’–GAGCTGTGATGTGAAGTTTCC–3’ and Rev 5’–
TCTGGGTTTGATCATTCTGTAG–3’. The annealing temperature was 60 °C for both. The levels of 
WNT1 and WNT3a were assessed using Taqman gene expression assays (Hs00180529_m1 and 
Hs00263977_m1, respectively) and normalized against TBP (Hs00427620_m1), following 
manufacturer’s instructions. Levels were determined based on the 2-∆∆Ct method, as previously 
described [69]. 
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Immunofluorescence (IF) 
U373 (shCtrl/shWNT6) and SNB19 (shCtrl/shWNT6) cells were plated in coverslips in 
DMEM supplemented with 10% FBS. Cells were fixed with paraformaldehyde 4% and then 
incubated in 1% BSA in PBS – 0.1% Tween for 1 hour. Afterwards, cells were incubated overnight 
at 4 ᵒC with the primary antibody against WNT6 or SOX2. Alexa fluor® 594 goat anti-rabbit IgG 
(H+L; A-11012, ThermoFisher Scientific) secondary antibody was used. Additionally, SOX2-
coverslips were incubated with anti-NESTIN primary antibody. Next, Alexa Fluor® 488 goat anti-
mouse IgG (H+L; A-11001, ThermoFisher Scientific) secondary antibody was used. DAPI 
(VECTASHIELD® Mounting Medium with DAPI, Vector Laboratories) was used to stain the cell 
nucleus (blue) at a concentration of 1.5 µg/mL. Further details about the antibodies used are 
provided in Supplementary Table S1. 
 
Cell viability assays 
Cell viability was determined 6 days after plating by both trypan blue and MTT (U373 and 
SNB19 cells) or MTS (U87 cells) assays. For trypan blue assay, cells were plated, in triplicate, at an 
initial density of 20 000 cells/well in 6-well plates. For MTT/MTS assay, transfected cells were 
plated in 12-well plates, in triplicate, at an initial density of 6 000 (for U373 and U87 cells) or 
10 000 cells/well (SNB19).  
For the MTT assay, cells were incubated with 0.5 mg of MTT (ThermoFisher Scientific) per 
mL of PBS 1x, during up to 2 hours in a humidified atmosphere at 37 ᵒC and 5% CO2. Subsequently, 
the formed crystals were dissolved using an acidified isopropanol solution (0.04 M HCl in 
isopropanol), as described in [70], and the absorbance was read at 570 nm. For the MTS assay, 
cells were incubated with 10% of the MTS solution (CellTiter 96® AQueous One Solution Cell 
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Proliferation Assay; Promega) in DMEM supplemented with 10% FBS, during up to 1h in a 
humidified atmosphere at 37 ᵒC and 5% CO2. Absorbance was recorded at 490 nm. 
 
Cell proliferation 
Cell proliferation was evaluated based on the measurement of BrdU incorporation during 
DNA synthesis (Cell Proliferation ELISA, BrdU colorimetric assay, Roche), as recommended by the 
manufacturer. Briefly, cells were cultured in DMEM (Gibco®) supplemented with 10% FBS 
(Biochrom) in 96-well plates (cell density: 2 000 cells/well) for 4 days. After that, BrdU was added 
to the cells and they were re-incubated for 4 hours. 
 
Cell migration 
Ibidi 2-well inserts (Ibidi) with a cell-free gap were used in 12-well plates to evaluate cell 
migration by wound healing assay. U373 and SNB19 transfected cells were plated in triplicate, at 
an initial density of 70 000 and 60 000 cells in each side of the insert, respectively, and left to 
adhere overnight. After that, inserts were removed (0 hours’ time-point) and wells were washed 
with PBS to remove dead cells and debris. The migration of the cells into the gap was imaged (2 
images/well) over hours until the wound closure was achieved (images were captured at the same 
localizations over time). The gap size (pixels) was measured using an automated software 
(beWound – Cell Migration Tool, v1.7, BESURG, Portugal; www.besurg.com) and manually verified 
and corrected when deemed necessary. At least 15 lines equally-spaced across the image and 
perpendicular to the gap main axis were used for increased measurement representativeness.  
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Cell invasion 
Cell invasion was assessed using the BD BioCoat™ Matrigel™ Invasion Chambers 
(Corning®) as recommended by the manufacturer. Briefly, cells were seeded into the top (insert) 
at the initial density of 50 000 cells/well (U373 and SNB19) or 25 000 cells/well (U87; 24-well 
chambers) in DMEM (Gibco®) supplemented with 1% FBS. EGF was added to the medium of the 
lower chamber (DMEM supplemented with 10% FBS) at the concentration of 20 ng/mL, as 
chemoattractant. Cells were incubated for 22 hours. Henceforth, cells that invaded through the 
membrane were stained using VECTASHIELD Mounting Medium with DAPI (Vector Laboratories) 
and a picture from the entire membrane was obtained using the Olympus Upright BX61 
microscope. The total cell number was counted with the help of the ImageJ software (version 
1.49). 
 
Cell death 
Cell death was evaluated after 6 days of treatment with TMZ (400 µM and 800 µM, for 
U373 and SNB19 transfected cells, respectively). TMZ treatment was applied 24 hours after 
plating and was renewed 2 days after. Cells were stained with Annexin V-FITC (BD Bioscience) and 
propidium iodide (PI; TermoFisher Scientific), according to manufacturer’s protocol, followed by 
flow cytometry analysis. A total of at least 10 000 events were acquired. Results were analyzed 
using the FlowJo software (version 10).  
 
Colony formation assay 
For clonogenic cell survival assay, cells were seeded at a density of 1 000 to 2 000 per 25-
cm2 flask, in triplicates. Twenty-four hours after seeding, irradiation was performed at RT in single 
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exposure doses, delivered by a Novalis TX® linear accelerator, with a nominal energy of 6 MV at 
a dose rate of about 400 cGy/min. Doses of 2 and 4 Gy were calculated using a dedicated 
treatment planning system to a depth of water of 1.5 cm. The plating efficiency (PE) represents 
the percentage of seeded cells that grew into colonies. Colonies with more than 50 cells were 
counted by microscopic inspection and PE, as well as the radiation-surviving fraction (PE of 
experimental group/PE of control group), were determined. Survival data were obtained with 
data from 3 independent experiments. 
 
Cell viability assay (MTT) under stem cell conditions 
Culture vessels were coated with natural mouse laminin (Invitrogen) for 3 hours at 37 ᵒC 
or overnight at 4 ᵒC at 10 µg/mL, as previously described [29]. U373 and SNB19 transfected cells 
were plated in 12-well laminin-coated plates, in triplicate, at an initial density of 6 000 and 10 000 
cells per well, respectively. Cells were cultured in serum-free stem cell medium composed by 
DMEM-F12 (Gibco) supplemented with 1x B27 (Invitrogen), 20 ng/mL of EGF (Invitrogen), and 20 
ng/mL of basic fibroblast growth factor (b-FGF, Invitrogen). After 4 days in culture, cells were 
incubated with MTT as detailed above (section Cell viability assays). 
 
Neurosphere formation assay 
U373, SNB19 and U87 transfected cells were plated at the maximum density of 4 000 
cells/mL in low-attachment 24-well plates (Corning). Cells were cultured in serum-free stem cell 
medium, as detailed above. Neurospheres were supplemented with fresh media every 4–5 days 
(250 µL/well). The number of neurospheres was counted after 10 days for U373 and U87 cells and 
15 days for SNB19. 
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Limiting Dilution Assay 
Cell numbers of U373 and U87 transfected cells were adjusted to a starting concentration 
of 40 000 cells/mL and 160 000 cells/mL, respectively, from which multiple serial dilutions were 
performed and plated in low-attachment 96-well plates (Corning). At the end, cell densities 
ranged from 1 000 to 1 cells per well in a final volume of 100 µL for U373 cells and from 4 000 to 
8 cells per well for U87 cells. Cells were cultured in serum-free stem cell medium, as detailed 
above. Cultures were disturbed only for media supplementation every 5 days. After 15 days, the 
fraction of wells not containing neurospheres was determined for each condition and plotted 
against the initially plated cellular density. Stem cell frequencies and statistical significance were 
calculated using the Extreme Limiting Dilution Assay (ELDA) software available at 
http://bioinf.wehi.edu.au/software/elda/ [71]. 
 
Stereotactic orthotopic xenografts 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice aged 4 months were anesthetized with a 
mixture of ketamine (75 mg/kg) and medetomidine (1 mg/kg) supplemented with butorphanol (5 
mg/kg) for its analgesic properties and placed into the digital 3-axis stereotaxic apparatus 
(Stoelting). A total of 5x105 U373- or 2x105 U87-transfected cells (resuspended in 5 µL PBS 1x) 
were injected into the brain striatum using a 10 µL Hamilton syringe with a point style 4 beveled 
26s-gauge needle, as previously described [72]. A total of 8 male and 6 female mice per group 
were used for U373- and U87-transfected cells, respectively. U373 and U87 cells were used as no 
reports were found for SNB19 tumorigenic capacity when orthotopically injected in 
immunocompromised mice. Mice were maintained under standard laboratory conditions, which 
- 26 - 
includes artificial 12 hours’ light/dark cycle, controlled ambient temperature (21 ± 1 ᵒC) and a 
relative humidity of 50 – 60%. The confirmation of specified pathogen free health status of 
sentinels’ mice maintained within the same animal room was performed according to FELASA 
guidelines. Experimental mice were always manipulated in a flow hood chamber, except during 
the surgery. Mice’ body weight was evaluated 3 times per week, while general behavior and 
symptomatology were registered daily. The pre-established humane endpoint was performed 
when mice presented severe weight loss (> 30% from maximum weight). Death was used for 
Kaplan-Meyer representation. 
 
Human phospho-kinase antibody array 
Human phospho-kinase antibody arrays (ARY003B; R&D systems) were used to 
simultaneously detect the relative levels of phosphorylation of 43 kinase phosphorylation sites 
and 2 related total proteins. Capture and control antibodies have been spotted in duplicate on 
nitrocellulose membranes. The protocol was done following manufacturer’s recommendations. 
In this case, 400 µg of total protein from all cell lines (U373 shCtrl/shWNT6 and SNB19 
shCtrl/shWNT6) was used. The obtained chemiluminescence was measured using the ChemiDoc 
imaging system (Biorad). Adjusted volume per spot (i.e. average pixel intensity of the spot times 
its area, corrected for the background) was measured using the Quantity One image analysis 
software. Background was eliminated using the local option. The average of each duplicated spot 
was calculated, normalized to HSP60 (reference protein) and used to determine the relative 
change in phosphorylated kinase proteins between shCtrl and shWNT6 conditions. Two sets of 
arrays were performed for U373 shCtrl/shWNT6, while only 1 was used for SNB19 shCtrl/shWNT6. 
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Western blot analysis 
Cells were washed with PBS 1x and removed by scratch in a lysis buffer containing 50 mM 
Tris pH 8, 2 mM EDTA pH 7.4, 0.1% SDS, 1% NP-40 and 150 mM NaCl, inhibitors of proteases 1x 
(B14001, Biotool) and phosphatases 1x (B15001, Biotool). After a 15-min incubation on ice, whole 
cell lysate was centrifuged at 13 000 x g for 15 min at 4 ᵒC. The total protein concentration was 
determined from the obtained supernatant using the PierceTM BCA protein assay kit 
(ThermoFisher Scientific), according to manufacturer’s protocol. Protein extracts (denatured and 
reduced; 20 µg/lane) were separated in a 10% SDS-polyacrylamide gel by electrophoresis and 
transferred to nitrocellulose membranes (Hybond-C Extra, GE Healthcare Life Sciences), using the 
Trans-blot turbo transferring system (Bio-rad), following manufacturer’s instructions. A protein 
ladder (Page ruler prestained protein ladder; Fermentas) was used to determine the approximate 
protein size, to monitor the progress of the electrophoretic run and the success of the transfer. 
Before starting the immunodetection, membranes were blocked with BSA (5% in TBS 1x), for 1 
hour at RT. The immunodetection was achieved using antibodies against p-STAT3 Y705, STAT3, 
non-p-β-catenin S33/S37/T41, β-catenin, p-AKT S473, AKT, and α-tubulin (see Supplementary 
Table S1 for details). Blots were revealed with peroxidase-conjugated secondary anti-mouse and 
anti-rabbit IgG antibodies (see Supplementary Table S1 for details), followed by enhanced 
chemiluminescence (ECL) solution (SuperSignal West Femto Chemiluminescent Substrate; 
Thermo Scientific). The obtained chemiluminescence was measured using the ChemiDoc imaging 
system (Biorad). If necessary, membranes were stripped using the Restore™ PLUS Western Blot 
Stripping Buffer (Thermo Fisher Scientific), following manufacturer’s recommendations. As for 
the phospho-kinase arrays, adjusted volume per band was measured using the Quantity One 
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image analysis software. Phosphorylated protein values were normalized to α-tubulin (reference 
protein). 
 
TCF/LEF reporter assay 
The Cignal TCF/LEF Reporter Assay Kit (GFP; Qiagen) was used to quantify the specific 
activation of β-catenin-dependent WNT signaling (canonical pathway). The protocol was done 
following manufacturer’s recommendations. Briefly, U373-shCtrl, U373-shWNT6, U87-Ctrl and 
U87-WNT6 cells were reverse transfected with i) a TCF/LEF reporter vector, which encodes a 
monster GFP under the control of a TATA box (basal promoter) joined to TCF/LEF responsive 
elements; ii) a negative control vector, which encodes GFP under the control of a TATA box; or iii) 
a positive control vector, which constitutively expresses the monster GFP for visual confirmation 
of the transfection efficiency. For this, cells were plated in triplicates, at an initial density of 20 000 
cells/well in a 96-well plate with black wall and clear bottom (Glass SPL Black plate). Lipofectamine 
3000 (Invitrogen) transfection reagent was used according to manufacturer’s recommendations 
(0.25 µL of Lipofectamine 3000 per 100 ng of DNA). After 16h of transfection, the medium was 
renewed and 24h post-transfection, cells were treated with 50 mM of LiCl. GFP expression was 
verified 24h after treatment under the microscope and quantified using the Varioskan Flash 
(Thermo Fisher Scientific) plate reader (excitation at 488 nm and emission at 515 nm). GFP 
expression in the reporter assay condition was normalized against the negative controls (as blank) 
and the respective positive controls (to control for transfection efficiency). 
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Gene Set Enrichment Analysis (GSEA) 
The raw expression data profile (Agilent G4502A 244K) of all GBM patients from TCGA (n 
= 573) was extracted as detailed above. GSEA (www.broad.mit.edu/gsea/) software was then 
used [73]. In this work, a continuous phenotype profile was employed to find gene sets that 
correlate with WNT6 (gene neighbors). Accordingly, the Pearson’s correlation was used to score 
and rank the genes. Gene sets from the Molecular Signature Database (MSigDb) C6 collection 
were used. Default options were used, unless otherwise stated. Significant enrichments were 
considered when false discovery rate (FDR) < 0.30. 
 
Statistical analyses 
Homoscedasticity was verified with the Levene’s test and differences between groups 
were assessed by a two-sided unpaired t-test, with the Welch’s correction being applied 
accordingly. For the wound healing assay and radiation treatment sensitivity assay, a two-way 
ANOVA followed by the post-hoc Sidak’s test for multiple comparison testing was used. For the 
TMZ treatment cell death assay, a two-way ANOVA followed by the post-hoc Tukey’s test for 
multiple comparison testing was used. The correlation between the expressions of WNT6 and 
stem-related genes (from the gene ontology gene-set 
GO_Positive_regulation_of_stem_cell_proliferation) was calculated using the Pearson’s 
correlation coefficient (r). The effects of WNT6 on mice OS was assessed by log-rank test. These 
analyses were performed with the GraphPad Prism 6.01 software (GraphPad software, Inc.). 
The Chi-square test was used to assess the difference between the distributions of tumors 
with high and low WNT6 expression stratified for LGGs and GBMs. To evaluate the prognostic 
value of WNT6 expression, univariate or multivariate analyses of survival were performed using, 
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respectively, the log-rank test or the Cox proportional hazard model, where the potential 
confounding effect of some variables is considered. These analyses were made with SPSS 22.0 
software (SPSS, Inc.). A meta-analysis including all datasets was performed with the 
Comprehensive Meta Analysis (CMA) v3 software (Biostat, Inc.). Hazard ratios and 95% 
confidence intervals from the Cox univariate or, when possible, multivariate analyses were used. 
A random effects statistical model was applied. 
For all statistical tests, significance was considered when p < 0.05.   
 
Study approval 
Written informed consent for investigation purposes was obtained from all patients. All 
procedures were in accordance with institutional ethics standards. Clinical samples in which 
patient information was collected were obtained from the Hospital Braga and Hospital Santa 
Maria, Portugal, and Hospital de Barretos, Brazil, with their respective ethical approvals (SECVS 
150/2014 and CNPD 7435/2011). All animal procedures were conducted in accordance with the 
guidelines for the care and use of laboratory animals (European Directive 2010/63/EU) and 
approved by the Direcção Geral de Alimentação e Veterinária (DGAV, reference 017761), the 
competent national authority for animal protection.   
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Figure 1. WNT6 is overexpressed at the mRNA and protein levels in GBM. 
(A) Expression levels of WNT6 in 27 lower-grade gliomas (LGG; grey dots), 572 glioblastomas 
(GBM, WHO grade IV; black and colored dots) and 10 unmatched normal brains (black unfilled 
dots) from TCGA. GBM molecular subtypes are represented in colors (red = classical; blue = 
proneural; green = neural; yellow = mesenchymal). WNT6 is overexpressed (TCGA data level 3 
values ≥ 0.41; above red dashed line) in 16% (n = 89) of GBM samples. (B) WNT6 protein 
expression in WHO grades I-IV glioma samples from Hospital Santo António cohort assessed by 
IHC (n = 63; p = 0.037; chi-squared test). Representative images are shown for a WNT6-negative 
GBM (a), high WNT6 expression in GBM (b) and WHO grade III anaplastic oligoastrocytoma (c), 
and a WHO grade II diffuse oligodendroglioma with intermediate levels of WNT6 expression (d). 
WNT6 staining was mostly cytoplasmic in glioma cells (closed arrowheads) and not present in 
lymphocytes (e; arrow), being almost exclusively negative for endothelial cells (b-d and f; open 
arrowheads). Bottom graph summarizes IHC data for the whole dataset. 
 
Figure 2. WNT6 promotes GBM aggressiveness in vitro. 
(A and B) The efficiency of WNT6 silencing in U373 and SNB19 glioblastoma cells was analyzed by 
qRT-PCR and WB (A), and immunofluorescence (B). (A) Top: WNT6 expression levels were 
normalized to TBP. Bottom: WB images are representative of 3 independent assays; α-tubulin 
was used as reference protein. (B) DAPI was used to stain the nucleus (40x magnification; scale 
bar = 50 µm). (C and D) Cell viability was measured by trypan blue (C) and MTT (D) assays in shCtrl 
and shWNT6 cells. (E) Cell proliferation was evaluated by BrdU incorporation. (F and G) Matrigel 
invasion assays were used to assess the cells’ invasion capacity. Representative images (F; cell 
nuclei stained with DAPI; scale bar = 250 µm) and quantification (G) of invasive U373 and SNB19 
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shCtrl and shWNT6 cells. (H – K) Migration (wound healing) assays were performed in U373 (H 
and I) and SNB19 (J and K) shCtrl and shWNT6 cells to assess the cells’ migration capacity. 
Representative micrographs throughout time for U373 (H) and SNB19 (J) cells (40x magnification; 
scale bar = 250 µm). The wound gap was measured and expressed as a percentage of wound 
closure for U373 (I) and SNB19 (K) cells (**** p <0.001; two-way ANOVA post-hoc Sidak’s test). 
Results represent data from at least 3 independent experiments (mean ± SD).  *, p < 0.05; **, p < 
0.01; ***, p < 0.005 and ****, p < 0.001 (otherwise stated, a two-sided unpaired t-test with 
Welch’s correction being applied when homoscedasticity was not verified).  
 
Figure 3. WNT6 promotes resistance to temozolomide chemotherapy in GBM cells. 
(A and B) U373 (A) and SNB19 (B) shCtrl- and shWNT6-transfected cells were treated with vehicle 
or TMZ for 6 days, and cell death was measured by Annexin-V and PI. The graphs present data of 
3 independent assays (mean ± SD). Representative dot plots are displayed below. *, p <0.05; **, 
p <0.01; ***, p < 0.001 and ****, p < 0.0001 (two-way ANOVA post-hoc Tukey’s test). 
 
Figure 4. WNT6 silencing decreases GBM stem cell features. 
(A) SOX2 and NESTIN double-immunostaining in U373 (left) and SNB19 (right) shCtrl/shWNT6 
cells. DAPI was used to stain cell nucleus (40x magnification; scale bar = 50 µm). (B) 
Representative images of U373 (left) and SNB19 (right) shCtrl/shWNT6 neurospheres at days 10 
and 15 after plating, respectively (40x magnification; scale bar = 250 µm). (C) Quantification of 
neurospheres formation (n = 3 independent assays; mean ± SD; *, p < 0.05; **, p < 0.01, two-
sided unpaired t-test with Welch’s correction being applied when homoscedasticity was not 
verified). (D) Limiting dilution assays in U373-shCtrl (black) and -shWNT6 (red) cells to assess their 
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sphere-forming capacity. The graph is representative of 3 independent assays with similar results. 
The trend lines represent the estimated active cell frequency (p = 0.01, likelihood ratio test). (E) 
Representative images of U373 (left) and SNB19 (right) shCtrl/shWNT6 cells cultured under stem 
cell adherent conditions (scale bar = 250 µm). (F) MTT assay evaluating U373 (left) and SNB19 
(right) shCtrl/shWNT6 cell viability when cultured under adherent stem cell conditions (n = 3 
independent assays; mean ± SD; **, p < 0.01; **** p < 0.0001; two-sided unpaired t-test with 
Welch’s correction being applied when homoscedasticity was not verified). (G) Heatmap 
representation of expression levels of WNT6 and 30 stem cell-related genes in 573 GBM patients’ 
samples from TCGA. Each column corresponds to a patient and each line to a gene. Expression 
values increase from darker blue (low levels) to darker red (high levels). (H) Correlation graphs 
between WNT6 expression (x-axis) and the expression of stem cell genes selected based on the 
heatmap (y-axis; Pearson’s correlation test r and p values are indicated). 
 
Figure 5. WNT6 accelerates GBM-associated death in an intracranial mice model. 
U373 transfected cells were orthotopically injected in the brain of NSG mice (n = 8 per group). (A) 
Weight curves after tumor implantation. (B) Kaplan-Meier overall survival curves of mice (p = 
0.0042; Log-rank test). (C – G) Post-mortem brain histological and molecular analyses. (C and D) 
H&E and anti-WNT6 IHC staining were used as controls for GBM formation and successful long-
term WNT6 silencing, respectively. (E – G) IHC for cell proliferation/viability markers Ki-67 and 
Cyclin D1 (E), stem cell markers SOX2 and NESTIN (F), and anti-apoptotic marker BCL2 (G). Scale 
bars’ values are shown in each microphotograph (20 µm or 50 µm). 
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Figure 6. WNT6 influences the activation status of WNT, SFK, and STAT pathways in GBM. 
Phospho-kinase arrays were performed to evaluate the phosphorylation status of cancer-related 
kinases in U373 (A) and SNB19 (B). Each array includes 2 technical replicates; 2 and 1 biological 
replicates were used for U373 and SNB19, respectively. Fold changes between phosphorylation 
levels of proteins in shWNT6 vs shCtrl cells are shown (means ± SDs). HSP60 was used as reference 
protein. Similar alterations in the phosphorylation of particular proteins for U373 and SNB19 cells 
are highlighted in red. *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.0001; two-sided 
unpaired t-test. (C and D) The phosphorylation status of STAT3, β-catenin, and AKT, and their 
respective total forms were assessed in U373 (C) and SNB19 (D) shCtrl and shWNT6 cells by WB 
(images are representative of 3 independent assays; α-tubulin was used as reference protein for 
normalization – relative expression levels are shown above each band). (E) GSEA analyses 
identifying signatures of genes significantly associated (ES > 0.3, and FDR < 0.3) with WNT6 in 
GBM patients from TCGA. 
 
Figure 7. WNT6 expression is prognostically valuable in GBM patients. 
Kaplan-Meier survival curves of WNT6-low and WNT6-high GBM patients derived from qRT-PCR 
data (A) or microarray (B-E) data. (A) Portuguese dataset, n = 51, median OS 16.9 vs 10.4 months 
(low vs high WNT6 expression, respectively; p = 0.032, Log-rank test). (B) Freije dataset, n = 59, 
median OS 9.6 vs 5 months (p = 0.006, Log-rank test). (C) Gravendeel dataset, n = 159, median OS 
10.1 vs 6 months (p = 0.029, Log-rank test). (D) Vital dataset, n = 26, median OS 18 vs 4 months 
(p = 0.02, Log-rank test). (E) Forest plot of hazard ratios (HR), illustrating the associations between 
WNT6 expression and overall survival in GBM patients. Each cohort is accompanied by its HR 
(black square; the size of the square represents the weight of the study in the meta-analysis) and 
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95% confidence intervals (extending lines). The diamond represents the estimated pooled effect 
(HR = 1.637; 95% confidence interval: 1.285 – 2.086; p < 0.0001).  
 
Figure 8. Proposed model for the functional, molecular and clinical impact of WNT6 in GBM. 
WNT6-high GBM cells present increased proliferation, invasion, migration, TMZ resistance and 
stem cell self-renewal capacities, which are accompanied by the activation of the WNT, SFK, RTK, 
STAT and AKT pathways. Clinically, WNT6-high tumors cause shorter overall survival (both in 
mouse GBM models and human patients). 
 
